“And we believe our dedicated teams have us on track to deliver against full year financial guidance.”

In context

“smokers to a smoke-free future. In the second quarter, our company's innovative smoke-free products delivered strong share and volume performance. And we hit meaningful milestones that we believe set us up for future success. NJOY received the first and only marketing granted orders from the FDA for menthol e-vapor products. And we submitted PMTA applications to the FDA For next-generation NJOY and on! products. Our traditional tobacco businesses remained resilient despite a challenging operating environment. Our highly cash-generative businesses supported continued investments in our innovative product efforts and we returned significant value to shareholders during the first half of the year, with more than $5.8 billion delivered to shareholders through share repurchases and dividends. And we believe our dedicated teams have us on track to deliver against full year financial guidance. This morning, my remarks will focus on NJOY's encouraging second quarter results, the state of the e-vapor category, illicit market activity and enforcement actions and strong second quarter results from on!. I'll then turn it over to Sal, who will provide further detail on our financial results, including our outlook, the performance of our traditional tobacco businesses and capital allocation. Let's begin with the e-vapor category. In June, we celebrated the 1-year anniversary of welcoming NJOY into the Altria family of companies. Since that time, we've combined our industry-leading capabilities with NJOY's competitive product offering and are thrilled with the progress we've made. Let me briefly recap some of our accomplishments. We strengthened NJOY's supply chain to enable our expans”